GILD Stock Continues Recovery From Monday’s FallGilead Sciences, Inc. (NASDAQ: GILD)GILD stocks fell hard Monday; losing more than two percent as the company issued a warning to doctors treating their patients with Sovaldi in combination with antiarrhythmics. However, the slide stopped and the stock started to move in the positive direction. Today, it seems as though the stock is staying […]
Source: Wikimedia Commons .How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the stock. The higher the target is above the current share price, the more highly the analysts view the stock.Analysts […]
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
By iCELL News on February 20, 2015 · Investing
SummaryIn 2015, the focus of the checkpoint inhibitor space will be on additional cancer types, beyond melanoma, as well as on collaborations and combinations.
The financial resources needed to develop an advantage in the anti-PD-1/PD-L1 space are now beyond the reach of most smaller […]
View gallery.Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the iShares Nasdaq Biotechnology Index (NASDAQ: IBB), hit two new […]
Small-cap biotechnology stocks offer some of the most breathtaking opportunities in the market, but some are better than others. For example, these three tiny biotech stocks are favorites among our Motley Fool experts, and that could mean they’re worth watching.Source: Portola Pharmaceuticals.: Warfarin’s decades long dominance as an anticoagulant used to treat heart disease and post-operative patients is waning, and […]
Source: Gilead Sciences.Gilead Sciences surprised investors when it recently announced that it will begin returning some of its cash stockpile to investors in the form of a dividend. Since dividend-paying biotech stocks are a bit of a rarity, we asked two Motley Fool healthcare experts for their opinion on whether Gilead Sciences’ dividend plan makes sense. Read on to learn […]
Source: Flickr user Simon & His Camera .Love is in the air, and that makes it the perfect time to confess my affection for three large-cap biotech stocks that market a slate of highly profitable, market-share leading therapies. Read on to learn more about why I have fallen for each of them.No. 1: Celgene CorporationWhile other companies hem and haw […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.’s David Martin has taken his seat in the grandstands, betting on specialty pharma and one day delivery cialis biotech companies based in Canada, where resource stocks have absorbed so much investment capital that […]
A doubling of Gilead Sciences ‘ sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences’ sales growth set to slow this year, investors may find that these three top biotech stocks prove to be a better bet in 2015.Source: Biogen Idec: Gilead Sciences’ slowing sales growth this year […]
